Overview
- Strive Specialties Inc. filed the case on Jan. 14 in the U.S. District Court for the Western District of Texas and is represented by BakerHostetler.
- The complaint claims Eli Lilly and Novo Nordisk coordinated to deter providers, patients, and telehealth platforms from using compounded GLP-1 drugs.
- Strive alleges the drugmakers’ partnerships with telehealth companies restrict those platforms from working with compounders, citing Novo’s canceled deal with Hims & Hers as an example.
- The pharmacy seeks injunctive relief and damages, arguing the conduct violates antitrust laws and limits patient choice for lawful compounded therapies.
- The lawsuit references earlier manufacturer citizen petitions and the FDA’s 2025 directive curbing semaglutide copycats; Lilly called the suit an attempt to shift focus, and Novo did not immediately comment.